Gater P R, Wasserman M A, Renzetti L M
Department of Inflammation/Autoimmune Diseases, Roche Pharmaceuticals, Hoffmann-La Roche Inc., Nutley, NJ 07110-1199, USA.
Eur J Pharmacol. 1996 May 23;304(1-3):123-8. doi: 10.1016/0014-2999(96)00125-2.
Endothelin exerts a variety of biological effects in the lung which indicate that this peptide may have a role in the pathophysiology of a number of pulmonary diseases. In this study, the endothelin receptors on the human bronchus were compared with those on the guinea-pig trachea using the novel, non-peptide antagonist Ro 47-0203 (4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2,2' -bipyrimidin-4-yl]-benzenesulphonamide, non-selective for endothelin ETA over endothelin ETB receptor) and the peptide antagonist BQ123 (cyclo(-D-Val-Leu-D-Trp-D-Asp-Pro), endothelin ETA receptor selective). On the human bronchus and guinea-pig trachea, the concentration-effect curve for endothelin-1 was shifted to the right by Ro 47-0203 (100 microM) with concentration ratios of 28.2 +/- 6.8 and 39.5 +/- 13.9, respectively but lower concentrations of the antagonist had no effect. Although the concentration-effect curve for sarafotoxin S6c on the human bronchus was shifted to the right by Ro 47-0203 (30 and 100 microM, concentration ratio: 6.88 +/- 1.72 and 69.7 +/- 17.2, respectively), equivalent degrees of inhibition could be obtained on guinea-pig trachea with lower concentrations of antagonist (10 and 30 microM, concentration ratio: 6.90 +/- 1.58 and 75.8 +/- 14.1 respectively). The lack of effect of BQ123 (10 microM) and the high concentrations of Ro 47-0203 needed to show antagonism indicate that endothelin receptors on both tissues are probably the endothelin ETB subtype. Although the antagonism by Ro 47-0203 is not classically competitive, the greater effect of Ro 47-0203 against sarafotoxin S6c on the guinea-pig trachea may reflect a difference between the endothelin ETB receptors on these tissues.
内皮素在肺中发挥多种生物学效应,这表明该肽可能在多种肺部疾病的病理生理学中起作用。在本研究中,使用新型非肽拮抗剂Ro 47 - 0203(4 - 叔丁基 - N - [6 - (2 - 羟基 - 乙氧基) - 5 - (2 - 甲氧基 - 苯氧基) - 2,2' - 联嘧啶 - 4 - 基] - 苯磺酰胺,对内皮素ETA受体与内皮素ETB受体无选择性)和肽拮抗剂BQ123(环(-D - 缬氨酸 - 亮氨酸 - D - 色氨酸 - D - 天冬氨酸 - 脯氨酸),内皮素ETA受体选择性),比较了人支气管和豚鼠气管上的内皮素受体。在人支气管和豚鼠气管上,Ro 47 - 0203(100μM)使内皮素 - 1的浓度 - 效应曲线右移,浓度比分别为28.2±6.8和39.5±13.9,但较低浓度的拮抗剂无作用。虽然Ro 47 - 0203(30和100μM,浓度比分别为6.88±1.72和69.7±17.2)使saratoxin S6c在人支气管上的浓度 - 效应曲线右移,但在豚鼠气管上用较低浓度的拮抗剂(10和30μM,浓度比分别为6.90±1.58和75.8±14.1)可获得同等程度的抑制。BQ123(10μM)无作用以及显示拮抗作用所需的Ro 47 - 0203高浓度表明,两种组织上的内皮素受体可能都是内皮素ETB亚型。虽然Ro 47 - 0203的拮抗作用并非典型的竞争性拮抗,但Ro 47 - 0203对豚鼠气管上saratoxin S6c的更大作用可能反映了这些组织上内皮素ETB受体之间的差异。